Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Sells 38,547 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Regulus Therapeutics Stock Performance

Shares of RGLS opened at $1.24 on Friday. The stock has a 50-day moving average of $1.52 and a two-hundred day moving average of $1.58. The stock has a market cap of $81.22 million, a P/E ratio of -1.16 and a beta of 1.60. Regulus Therapeutics Inc. has a one year low of $1.13 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics during the third quarter worth $10,154,000. State Street Corp grew its position in Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after purchasing an additional 33,496 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $1,403,000. Victory Capital Management Inc. lifted its holdings in shares of Regulus Therapeutics by 10.4% in the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 37,480 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Regulus Therapeutics in the second quarter worth about $352,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.